Progressive anemia following combination therapy with interferon-α and interleukin-2 in a patient with metastatic renal cell carcinoma

被引：0
|
作者：
Hosokawa, Y
Kishino, T
Ono, T
Oyama, N
Hayashi, K
Momose, H
机构：
[1] Hoshigaoka Koseinenkin Hosp, Dept Urol, Osaka 5738511, Japan
[2] Hoshigaoka Koseinenkin Hosp, Dept Hematol, Osaka 5738511, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2004年 / 11卷 / 10期
关键词：
autoimmunity; hemolytic anemia; interleukin-2;
D O I：
10.1111/j.1442-2042.2004.00914.x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Various toxicities have been observed during the treatment of advanced renal cell carcinoma with interferon-alpha (IFN-alpha) and/or interleukin-2 (IL-2). We report a case of severe anemia, which responded well to steroid therapy, in a patient receiving IL-2 plus IFN-alpha for metastatic renal cell carcinoma.
引用
收藏
页码：906 / 908
页数：3
相关论文
共 50 条
  • [21] A randomized phase II trial of interleukin-2/interferon-α plus bevacizumab versus interleukin-2/interferon-α in metastatic renal cell carcinoma (mRCC): Results from the Danish Renal Cancer Group (DARENCA) study 1
    Donskov, Frede
    Jensen, Niels Viggo
    Smidt-Hansen, Torben
    Brondum, Line
    Geertsen, Paul F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] MULTIINSTITUTIONAL HOME-THERAPY TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-2 AND INTERFERON ALFA-2 IN PROGRESSIVE METASTATIC RENAL-CELL CARCINOMA
    ATZPODIEN, J
    HANNINEN, EL
    KIRCHNER, H
    BODENSTEIN, H
    PFREUNDSCHUH, M
    REBMANN, U
    METZNER, B
    ILLIGER, HJ
    JAKSE, G
    NIESEL, T
    SCHOLZ, HJ
    WILHELM, S
    PIELMEIER, T
    ZAKRZEWSKI, G
    BLUM, G
    BEIER, J
    MULLER, GW
    DUENSING, S
    ANTON, P
    ALLHOFF, E
    JONAS, U
    POLIWODA, H
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) : 497 - 501
  • [23] SURGICAL RESECTION FOLLOWING INTERLEUKIN-2 THERAPY FOR METASTATIC RENAL-CELL CARCINOMA PROLONGS REMISSION
    KIM, B
    LOUIE, AC
    ARCHIVES OF SURGERY, 1992, 127 (11) : 1343 - 1349
  • [24] Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma
    Fallick, ML
    McDermott, DF
    LaRock, D
    Long, JP
    Atkins, MB
    JOURNAL OF UROLOGY, 1997, 158 (05): : 1691 - 1695
  • [25] INTERLEUKIN-2 BY INHALATION - LOCAL THERAPY FOR METASTATIC RENAL-CELL CARCINOMA
    HULAND, E
    HULAND, H
    HEINZER, H
    JOURNAL OF UROLOGY, 1992, 147 (02): : 344 - 348
  • [26] Natural history and therapy of metastatic renal cell carcinoma - The role of interleukin-2
    Bukowski, RM
    CANCER, 1997, 80 (07) : 1198 - 1220
  • [27] Dexamethasone and interleukin-2 combination therapy for advanced renal cell carcinoma in a patient with paraneoplastic inflammatory syndrome
    Shinojima, T
    Oya, M
    Kohno, H
    Marumo, K
    Murai, M
    INTERNATIONAL JOURNAL OF UROLOGY, 2004, 11 (07) : 553 - 556
  • [28] Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil
    Négrier, S
    Caty, A
    Lesimple, T
    Douillard, JY
    Escudier, B
    Rossi, JF
    Viens, P
    Gomez, F
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (24) : 4009 - 4015
  • [29] A randomized phase II trial of interleukin-2 and interferon- plus bevacizumab versus interleukin-2 and interferon- in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1
    Donskov, Frede
    Jensen, Niels Viggo
    Smidt-Hansen, Torben
    Brondum, Line
    Geertsen, Poul
    ACTA ONCOLOGICA, 2018, 57 (05) : 589 - 594
  • [30] Delirium after interleukin-2 and alpha-interferon therapy for renal cell carcinoma
    Van Steijn, JHM
    Nieboer, P
    Hospers, GAP
    De Vries, EGE
    Mulder, NH
    ANTICANCER RESEARCH, 2001, 21 (05) : 3699 - 3700
12345